Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.

[1]  R. Braun,et al.  Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. , 2011, Swiss medical weekly.

[2]  G. Arcangeli,et al.  Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology , 2009, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[3]  A. Hauschild,et al.  Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Mariamma G. Joseph,et al.  Topical Imiquimod Therapy for Lentigo Maligna , 2008, Annals of plastic surgery.

[5]  N. Yawalkar,et al.  Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. , 2008, Archives of dermatology.

[6]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[7]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[8]  M. Weichenthal,et al.  Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Hauschild,et al.  Short German guidelines: Malignant melanoma , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  A. Bembenek,et al.  Long-Term Survival in Stage IV Melanoma after Repetitive Surgical Therapy , 2008, Oncology Research and Treatment.

[11]  A. Hauschild,et al.  Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. , 2008, Melanoma research.

[12]  A. Hauschild,et al.  Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma , 2008, Cancer.

[13]  A. Hauschild,et al.  Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. , 2008, Melanoma research.

[14]  G. Bowen,et al.  Treatment of Lentigo Maligna with Imiquimod before Staged Excision , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[15]  A. Hauschild,et al.  Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. , 2007, Melanoma research.

[16]  A. Enk,et al.  Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routine , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  P. Brown,et al.  A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma , 2007, Cancer.

[18]  A. Hauschild,et al.  Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. , 2007, European Journal of Surgical Oncology.

[19]  V. Sondak,et al.  Surgical therapy of cutaneous melanoma. , 2007, Seminars in oncology.

[20]  J. Grob,et al.  Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report. , 2007, European journal of dermatology : EJD.

[21]  P. Chapman,et al.  Adjuvant Therapy of Melanoma , 2007, Cancer journal.

[22]  J. Houwing-Duistermaat,et al.  From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. , 2007, Journal of the American Academy of Dermatology.

[23]  C. Garbe,et al.  Diagnosis and treatment of cutaneous melanoma: state of the art 2006. , 2007, Melanoma research.

[24]  D. Bishop,et al.  Management of familial melanoma. , 2007, The Lancet. Oncology.

[25]  H. Shaw,et al.  Sentinel node mapping for melanoma: results of trials and current applications. , 2007, Surgical oncology clinics of North America.

[26]  M. McDermott,et al.  Gamma Knife radiosurgery for brainstem metastases: the UCSF experience , 2007, Journal of Neuro-Oncology.

[27]  N. Spry,et al.  A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[29]  J. Arlette,et al.  Mohs micrographic surgery in the treatment of lentigo maligna and melanoma , 2006, Journal of surgical oncology.

[30]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Régis,et al.  Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[32]  D. Jukic,et al.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Ingle,et al.  Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma , 2006, Cancer.

[34]  D. Schadendorf,et al.  Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Ross,et al.  Is incisional biopsy of melanoma harmful? , 2005, American journal of surgery.

[36]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[37]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.

[38]  D. Lawson.  Choices in adjuvant therapy of melanoma. , 2005, Cancer control : journal of the Moffitt Cancer Center.

[39]  V. Sondak,et al.  Cutaneous melanoma: methods of biopsy and definitive surgical excision , 2005, Dermatologic therapy.

[40]  A. Blum,et al.  Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy , 2005, The British journal of dermatology.

[41]  O. Stevenson,et al.  Lentigo Maligna , 2005, American journal of clinical dermatology.

[42]  R. Dummer,et al.  Updated Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma , 2004, Dermatology.

[43]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[44]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[45]  M. Gore,et al.  Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  C. Garbe,et al.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.

[47]  F. Bray,et al.  Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia , 2003, International journal of cancer.

[48]  V. Sondak,et al.  Pros and cons of adjuvant interferon in the treatment of melanoma. , 2003, The oncologist.

[49]  D. Elder,et al.  Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. , 2003, European journal of cancer.

[50]  C. Garbe,et al.  Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. , 2003, Pigment cell research.

[51]  S. Ugurel,et al.  Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study , 2003, Anti-cancer drugs.

[52]  A. Hauschild,et al.  Surgical Standards in the Primary Care of Melanoma Patients , 2003, Oncology Research and Treatment.

[53]  C. Garbe,et al.  Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients , 2003, Cancer.

[54]  A. Hauschild,et al.  A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.

[55]  A. Blum,et al.  Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Walton.  Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. , 2002 .

[57]  M. Nicolson,et al.  Incidence of and survival from malignant melanoma in Scotland: an epidemiological study , 2002, The Lancet.

[58]  J. J. van den Oord,et al.  Pathologic staging of melanoma. , 2002, Seminars in oncology.

[59]  D. Schadendorf,et al.  Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival , 2002, British Journal of Cancer.

[60]  H. Kittler,et al.  Diagnostic accuracy of dermoscopy. , 2002, The Lancet. Oncology.

[61]  D. Schadendorf.  Is There a Standard for the Palliative Treatment of Melanoma? , 2002, Oncology Research and Treatment.

[62]  J. A. Bishop,et al.  British Association of Dermatologists Clinical Standards Unit. Revised U.K. guidelines for the management of cutaneous melanoma , 2010 .

[63]  U. Ringborg,et al.  Trends in Incidence of Cutaneous Malignant Melanoma in a Swedish Population 1976-1994 , 2002, Acta oncologica.

[64]  J. Dunn,et al.  Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma , 2001 .

[65]  A. Blum,et al.  Epidemiology of Cutaneous Melanoma in Germany and Worldwide , 2001, Skin Pharmacology and Physiology.

[66]  N. Cascinelli,et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.

[67]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Gore,et al.  Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study , 2001, British Journal of Cancer.

[70]  A. Paccagnella,et al.  Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients , 2001, Melanoma research.

[71]  T. Lehnert,et al.  Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients , 2001, International Journal of Clinical Oncology.

[72]  A. Blum,et al.  Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? , 2000, Melanoma research.

[73]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  G. Rassner,et al.  Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. , 1999, The American journal of surgical pathology.

[76]  Y. Kirova,et al.  Radiotherapy as palliative treatment for metastatic melanoma. , 1999, Melanoma research.

[77]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[78]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  K. Rowland,et al.  Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[82]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  S. Aamdal,et al.  Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. , 1998, European journal of cancer.

[84]  C. Chastang,et al.  Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.

[85]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Binder,et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  R. Meuli,et al.  Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  S. Legha,et al.  Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma , 1996, Cancer.

[90]  J. Kugler,et al.  Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  H. Soyer,et al.  Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. , 1994, The Journal of investigative dermatology.

[93]  P. Queirolo,et al.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  D. Pectasides,et al.  Adjuvant Chemotherapy With Dacarbazine, Vindesine, and Cisplatin in Pathological Stage II Malignant Melanoma , 1994, American journal of clinical oncology.

[95]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[96]  K. Smith,et al.  Interferon alpha2a and vindesine in the treatment of advanced malignant melanoma , 1992 .

[97]  W. Fridman,et al.  IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. , 1992, Biotechnology therapeutics.

[98]  R. Elashoff,et al.  Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .

[99]  M. Namer,et al.  Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.

[100]  J. Grob,et al.  Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma , 1990, Cancer.

[101]  D. Longo,et al.  Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. , 1989, Cancer research.

[102]  H. Strander,et al.  Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II study , 1989, Medical oncology and tumor pharmacotherapy.

[103]  L. Solin,et al.  Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. , 1988, International journal of radiation oncology, biology, physics.

[104]  J. Mulder,et al.  Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group , 1988, Cancer.

[105]  A. Foltz,et al.  Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma , 1988, Cancer.

[106]  M. Pilepich,et al.  Analysis of dose fractionation in the palliation of metastases from malignant melanoma , 1988, Cancer.

[107]  S. Gundersen.  Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. , 1987, Cancer treatment reports.

[108]  E. Holly,et al.  Number of melanocytic nevi as a major risk factor for malignant melanoma. , 1987, Journal of the American Academy of Dermatology.

[109]  M. Mastrangelo,et al.  Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. , 1987, Cancer treatment reports.

[110]  R. Spiegel,et al.  Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. , 1986, Immunobiology.

[111]  B. Peterson,et al.  Vindesine for metastatic malignant melanoma. A phase II trial. , 1983, American Journal of Clinical Oncology.

[112]  K. Calman,et al.  A multicentre phase II trial of vindesine in malignant melanoma. , 1982, European journal of cancer & clinical oncology.

[113]  C. Fabian,et al.  Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study. , 1982, Medical and pediatric oncology.

[114]  H. Katz.  The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. , 1981, International journal of radiation oncology, biology, physics.

[115]  A. Huang,et al.  DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma , 1980, Cancer.

[116]  E. Krementz,et al.  DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). , 1976, Cancer treatment reports.

[117]  W. Clark,et al.  The classification of malignant melanoma and its histologic reporting , 1973, Cancer.

[118]  W. Clark,et al.  The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. , 1971, The New England journal of medicine.

[119]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.